Our GLP-1 meal plan guide covers this in detail
Due to their poor bioavailability when administered orally, peptide therapies typically require injection, which can impact on adherence, particularly in chronic diseases where long-term treatment is needed [2, 5,6,7]
Clinical studies, including the STEP (Semaglutide GLP-1 Treatment Effect in People with Obesity) trials, have shown that participants experienced an average weight loss of about 15% over 68 weeks
By doing so, you are taking an important step toward better health and effective weight loss
Semaglutide, although less commonly associated with kidney issues, can indirectly stress the kidneys in people who experience severe dehydration due to vomiting or diarrhea (common side effects)